A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars
State explicitly what error bars represent (e.g. SD, SE, CI) Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
DeSeq2 and rMATS were used to generate both RNASeq and splicing analyses, respectively.
Data analysis
Gene Set Enrichment Analysis (GSEA), Excell, GraphPad, Prism 8, Image J, DeSeq2, IGV 2.3.91, FlowJo LLC, rMATS.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample size for xenograft experiment was defined by using 2-Sample T-Test method.
Data exclusions No animal was excluded from the experiments.
Replication
For all experiments, all replicates are mentioned in the figure legends.
Randomization No randomization of mice was used. Mice analysed were litter mates and age-matched whenever possible.
Blinding
No blinding was done during the experiment as mice were injected with control or RNF113A-depleted cells in each flanck.
Materials & experimental systems
Policy information about availability of materials n/a Involved in the study
Unique materials
Antibodies Eukaryotic cell lines
Research animals
Human research participants Antibodies Antibodies used
All antibodies used in the study are listed in Table S9 .
Validation
For commercial antibodies, no additional validation was performed. For our home-made anti-RNF113A antibody, the validation was performed by carrying out western blot analyses with control and RNF113A-depleted A549 cells (lentiviral infections).
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s)
Cell lines source is stated in the Method section of the manuscript.
Authentication
No authentication of the cell lines was performed by us. This authentification was carried out by ATCC.
Mycoplasma contamination
Mycoplasma was checked routinely. Only cells found negative for mycoplasma were used in this study. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology

Sample preparation
The Annexin-V-FLUOS Staining Kit (Roche) was used to access cell death following the manufacturer's instructions, using the FACSCalibur flow cytometer (BD Biosciences). For the measurement of lipid peroxidation, control or RNF113A-depleted A549 cells treated or not with Cisplatin (25 micromolar for 24 hours), were incubated for 30 minutes at 37°C in a medium supplemented with 5 micromolar C-11 BODIPY (Invitrogen). Cells were analysed on FACS Canto II and the data were generated using the FlowJo program. For ROS measurement, control or RNF113A-depleted A549 cells treated or not with Cisplatin 25 micromolar for 24 hours) were incubated for 10 minutes at 37°C in a carboxy-H2DFFDA-containing solution at a concentration of 24 micromolar (Invitrogen). Cells were analysed on FACS Canto II and the data were generated using the FlowJo program.
Instrument
For cell death assay: FACS Calibur2Lasers and FACS Canto II.
Software
FlowJo, BD FACSDiva software.
Cell population abundance No sorting was performed.
Gating strategy
For all FACS analyses, the gating strategy used was forward and side scatter gating -to remove debris and other events of noninterest while preserving cells based on size and or complexity.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
